Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.46 |
| ▸ | CNR2 | P34972 | 8/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | MLNR | O43193 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | CCKAR | P32238 | 1/20 | 0.45 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358466 | 0.86 | CNR1 (0.55) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL5370602 | 0.85 | CNR2 (0.58) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL5368461 | 0.85 | CNR1 (0.56) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL5374690 | 0.84 | CNR2 (0.54) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL5370544 | 0.81 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5371206 | 0.77 | CNR2 (0.53) | CNR1CNR2CYP2C9GPR55 | |
| SCHEMBL5371083 | 0.76 | CNR1 (0.50) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL5375151 | 0.76 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5364111 | 0.76 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL5370352 | 0.75 | CNR1 (0.57) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER, INC. | 2007-11-01 | — | — | US | claimed |
| JP-2007502808-A | — | — | 2007-02-15 | — | — | JP | claimed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| JP-2006514942-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1626738-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1624895-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| EP-1572662-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2005018645-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043327-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| WO-2004098641-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098580-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040224962-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| WO-2004052864-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-06-24 | — | — | US | claimed |
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER, INC. | 2007-11-01 | — | — | US | disclosed |
| US-7247628-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | disclosed |
| WO-2004052864-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885ABCC4 2723/4885 |
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885ABCC4 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.